Rock Hill, S.C. — A global biopharmaceutical company, whose identity had been a closely guarded secret under the codename Project Palmetto Rock, has officially announced its plans for a massive $1.5 billion investment in Rock Hill. Swiss-based Octapharma, a privately owned plasma fractionator, confirmed its intentions at a York County Council public hearing on Monday, June 29, 2026, detailing a project that will establish a significant U.S. corporate headquarters campus and a state-of-the-art manufacturing facility.
The ambitious undertaking is projected to create more than 1,200 new jobs in Rock Hill, with an additional 300 executive positions relocating from Octapharma Plasma, a subsidiary currently based in Charlotte. This brings the total new and relocated jobs to over 1,500, marking one of the largest economic development projects ever introduced in York County.
Octapharma specializes in creating life-saving medicines and therapies derived from human plasma and cell lines. These treatments address a range of critical conditions, including immune disorders, haematological diseases, and needs in critical care. The company, headquartered in Lachen, Switzerland, southeast of Zurich, prides itself on being the world’s largest privately owned plasma fractionator, a process that separates plasma into its individual therapeutic components.
The new Rock Hill facility will significantly bolster Octapharma’s global operational capacity, adding 3.5 million liters of plasma processing capability. This represents approximately one-third of the company’s worldwide capacity. Historically, about 88% of the plasma donations utilized by Octapharma originate in the U.S. but are then shipped to manufacturing sites in Europe for processing. The establishment of the Rock Hill plant will re-route this collected plasma, allowing for domestic processing and a more streamlined supply chain for critical medicines.
The investment is slated to unfold over a decade, with construction on the corporate headquarters and manufacturing facility anticipated to commence in late 2026. The chosen site for this expansive development is the former Carolina Panthers property in Rock Hill, specifically where Palmetto Parkway intersects with the interstate.
The economic impact of these new jobs is substantial. Headquarters positions are expected to command an average annual salary exceeding $141,000, while manufacturing roles will average nearly $103,000 per year. These figures underscore the high-value nature of the employment opportunities Octapharma is bringing to the region.
Octapharma’s public disclosure on June 29 followed a period of intense speculation and a non-disclosure agreement involving Rock Hill and York County officials, under which the project was known as Project Palmetto Rock. The formal announcement allowed for public discussion and the initial steps toward approving tax incentive agreements for the project.
### Why it matters in Aiken
The arrival of a major biopharmaceutical player like Octapharma in South Carolina, with an investment of $1.5 billion and the creation of over 1,500 high-paying jobs, represents a significant economic shift within the state. While geographically distant from Aiken, this development highlights the competitive landscape for attracting large-scale industries and skilled labor across the Central Savannah River Area. Institutions such as the University of South Carolina Aiken, which educates a local workforce, and major employers like Savannah River Nuclear Solutions and Aiken Regional Medical Centers, could experience indirect impacts. The demand for specialized talent in advanced manufacturing and healthcare, spurred by projects like Octapharma’s, could intensify competition for graduates and experienced professionals, influencing regional wage scales and talent retention strategies in Aiken County and beyond. This expansion underscores South Carolina’s growing appeal for high-tech manufacturing and life sciences, setting a benchmark for future economic development efforts across the state.
